Semaglutide vs Zovaglutide: Weekly vs Monthly GLP-1 Agonists

Introduction#

Semaglutide and zovaglutide are both selective GLP-1 receptor agonists, but they represent different approaches to dosing frequency. Semaglutide (Ozempic/Wegovy/Rybelsus) is the current standard-of-care GLP-1 agonist with once-weekly injectable and daily oral formulations. Zovaglutide, developed by Beijing QL Biopharmaceutical, is designed as a potential once-monthly injectable GLP-1 agonist, which would reduce injection frequency by 4-fold compared to weekly semaglutide.

This comparison examines the clinical evidence, pharmacological differences, and the tradeoffs between semaglutide's proven track record and zovaglutide's convenience-focused development. It is important to note the substantial asymmetry in evidence: semaglutide has data from tens of thousands of patients across Phase 3 and real-world settings, while zovaglutide has only Phase 2 data from 303 patients over 24 weeks.

Mechanism of Action Comparison#

Semaglutide#

Semaglutide is a 31-amino acid human GLP-1 analog with three key modifications: an Aib substitution at position 2 for DPP-4 resistance, a C18 fatty diacid at Lys26 for albumin binding, and an Arg substitution at position 34 to prevent mis-acylation. These produce a half-life of approximately 165 hours (7 days), enabling true once-weekly pharmacokinetics from molecular design alone.

Zovaglutide#

Zovaglutide is a GLP-1 receptor agonist featuring a dual fatty acid chain modification that enhances binding affinity to serum albumin beyond what single-chain modifications achieve. This produces a substantially longer half-life than semaglutide, supporting once-monthly (every 4 weeks, Q4W) administration. The molecule was also tested at a twice-monthly (Q2W) dosing interval.

Pharmacokinetic Comparison#

Weight Loss Efficacy#

Semaglutide (STEP Program)#

Semaglutide's obesity efficacy is established across multiple large Phase 3 trials:

• STEP 1 (1,961 adults without T2D): 14.9% mean weight loss at 2.4 mg over 68 weeks; 86.4% achieved 5% or more; 50.5% achieved 15% or more
• STEP 2 (1,210 adults with T2D): 9.6% mean weight loss
• STEP 3 (with behavioral therapy): 16.0% mean weight loss
• STEP 5 (2-year data): 15.2% sustained weight loss at 104 weeks

Zovaglutide (Phase 2)#

Zovaglutide Phase 2 results (presented at EASD 2025) enrolled 303 overweight or obese adults across five dose arms over 24 weeks:

Cross-Trial Comparison (Important Caveats)#

Zovaglutide's Phase 2 results (10.6-14.4% at 24 weeks) suggest a competitive weight loss trajectory, but several critical differences preclude direct comparison:

1. Duration: 24 weeks (zovaglutide) vs 68 weeks (semaglutide STEP 1). Weight loss typically continues beyond 24 weeks.
2. Population size: 303 (zovaglutide) vs 1,961 (STEP 1). Smaller trials often show larger effect sizes.
3. Trial phase: Phase 2 vs Phase 3. Phase 2 results often do not fully replicate in Phase 3.
4. Population: May differ in baseline BMI, demographics, and other characteristics.

The weight loss trajectory of zovaglutide at 24 weeks appears comparable to semaglutide's trajectory at the same time point in STEP 1, but longer-duration Phase 3 data are needed to confirm this.

Cardiovascular and Long-Term Evidence#

Semaglutide#

• SELECT trial (17,604 patients, 39.8 months): 20% MACE reduction in overweight/obese adults without diabetes (HR 0.80, p<0.001)
• SUSTAIN 6 (3,297 patients): 26% MACE reduction in T2D
• STEP 5: 15.2% weight loss sustained at 2 years
• STEP 4: Weight regain of approximately two-thirds after drug withdrawal
• Extensive post-marketing real-world data (8+ years)

Zovaglutide#

• No cardiovascular outcomes trial completed or planned
• No data beyond 24 weeks
• No real-world post-marketing experience
• Phase 3 planned but not yet initiated

The evidence gap is substantial. Semaglutide's cardiovascular outcomes data and multi-year safety experience cannot be replicated quickly; zovaglutide would require years of Phase 3 trials and post-marketing surveillance to approach comparable evidence maturity.

Dosing and Administration#

Semaglutide#

• Wegovy (obesity): 0.25 mg weekly, titrate monthly to 2.4 mg over 16 weeks
• Ozempic (T2D): 0.25 mg weekly, titrate to 0.5 mg, max 2.0 mg
• Rybelsus (T2D): 3 mg daily oral, escalate to 7 mg, max 14 mg
• Oral semaglutide 25 mg (approved 2025): Oral for weight management
• 52 injections per year (injectable) or daily oral

Zovaglutide#

• Phase 2 tested 80 mg and 160 mg at Q4W (monthly) and Q2W (biweekly) intervals
• Monthly dosing (Q4W): 12-13 injections per year
• Biweekly dosing (Q2W): 26 injections per year
• Final dose and schedule will be determined by Phase 3
• No oral formulation

The monthly dosing proposition is zovaglutide's most compelling differentiator. Reducing injections from 52 to 12-13 per year could meaningfully improve long-term adherence, particularly for patients who find weekly injections burdensome.

Safety Comparison#

Semaglutide#

Well-characterized safety profile across thousands of patients:

• GI adverse events: 50-70% (mostly mild-moderate, dose-escalation related)
• Discontinuation due to AEs: ~7% (STEP 1)
• Boxed warning: Thyroid C-cell tumors (rodent data)
• Post-marketing signals: Pancreatitis, gallbladder events, ileus (rare)
• 8+ years of post-marketing surveillance

Zovaglutide#

Phase 2 safety data (303 patients, 24 weeks):

• GI adverse events: Present but low severity
• Discontinuation due to GI AEs: 1.3% (notably low for GLP-1 class)
• Monthly dosing showed fewer GI events than biweekly dosing
• No long-term safety data available
• No post-marketing experience

The 1.3% GI-related discontinuation rate is notably lower than typical GLP-1 agonists (5-10%). If confirmed in Phase 3, this could represent a meaningful tolerability advantage. The monthly dosing interval may inherently reduce GI side effects by avoiding the peak-trough fluctuations associated with more frequent dosing.

Key Differences Summary#

Conclusion#

Semaglutide is the proven standard-of-care with decades of clinical trial data, cardiovascular outcomes evidence, real-world validation, and multiple formulation options. Zovaglutide's once-monthly dosing represents a genuine advancement in patient convenience that could improve long-term adherence if Phase 3 trials confirm the promising Phase 2 results. The 1.3% GI discontinuation rate is encouragingly low. However, zovaglutide is years away from potential approval, has only 303 patients studied over 24 weeks, and lacks any long-term safety or cardiovascular outcomes data. For current treatment decisions, semaglutide is the clear choice. Zovaglutide should be watched as a potentially important next-generation option for patients who prioritize minimal injection frequency.

Further Reading#

• Semaglutide Overview and Research Guide
• Semaglutide Side Effects
• Semaglutide Dosing Protocols
• Zovaglutide Overview and Research Guide
• Zovaglutide Side Effects
• Zovaglutide Dosing Protocols